Long-term efficacy and safety of ruxolitinib in polycythaemia vera

Affiliations

¹ Department of Hematology, Shinmatsudo Central General Hospital, Matsudo 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Navitas Clinic Kawasaki, Kanagawa, Japan.

Comment

Motoharu Shibusawa et al. Lancet Haematol. 2020 Jul.

. 2020 Jul;7(7):e505-e506.

doi: 10.1016/S2352-3026(20)30102-2.

¹ Department of Hematology, Shinmatsudo Central General Hospital, Matsudo 270-0034, Japan. Electronic address: m_sibusawa@hotmail.com.
² Navitas Clinic Kawasaki, Kanagawa, Japan.

No abstract available

Comment in

Long-term efficacy and safety of ruxolitinib in polycythaemia vera - Authors' reply.
Kiladjian JJ. Kiladjian JJ. Lancet Haematol. 2020 Jul;7(7):e506. doi: 10.1016/S2352-3026(20)30141-1. Lancet Haematol. 2020. PMID: 32589974 No abstract available.

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Cell Therapy Transplant Canada. Walker I, et al. Lancet Haematol. 2020 Feb;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0. Epub 2020 Jan 17. Lancet Haematol. 2020. PMID: 31958417 Clinical Trial.